logo

For the Inventor, By the Inventor

Mishima, Japan

Takayuki Maruyama

This inventor holds 20 USPTO granted patents and 3 published patent applications and 3 EPO patents, primarily in Pharmaceutical Composition. Top assignees: Ono Pharmaceutical Co., Ltd., Ono Pharmaceuticals Co., Ltd., Hamamatsu University School of Medicine. Active years: 1997-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takayuki Maruyama. Retrieved from https://idiyas.com/inventor/takayuki-maruyama-hwcr3n5c

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 20 

% Patents Active = 30.0

 

Average Co-Inventor Count = 3.3

ph-index = 6

Forward Citations = 132(Granted Patents)


Location History:

  • Mishima, JP (1998 - 2000)
  • Osaka, JP (2001 - 2013)
  • Mishima-gun, JP (1997 - 2017)

Company Filing History:

goldMedal16 out of 575 
 
Ono Pharmaceutical Co., Ltd.
 patents
silverMedal2 out of 22 
 
Ono Pharmaceuticals Co., Ltd.
 patents
bronzeMedal1 out of 43 
 
Hamamatsu University School of Medicine
 patents
4. 1 out of 1 
 
Katsuhiko Mikoshiba
 patent
5. 1 out of 388 
 
Nipro Corporation
 patents
6. 1 out of 5 
 
Ono Pharmaceuticalco.,ltd.
 patents
7. 1 out of 1,045 
 
Osaka University
 patents
where one patent can have more than one assignee

Years Active: 1997-2017

Loading Chart...
Loading Chart...
Areas of Expertise:
Heart Failure Treatment
Pharmaceutical Composition
Bone Mass Disease
EP4 Agonist
N-Phenylarylsulfonamide
Cytotoxic T Cell Activator
Calcium Inhibitors
Benzoic Acid Derivatives
Depression Remedies
Naphthyloxyacetic Acid
Therapeutic Agent
20 patents (USPTO):Explore Patents
1. 9597436 - Advanced heart failure treatment material as myocardial/cardiovascular regeneration device (2017-03-21),
2. 9181187 - Therapeutic agent for urinary excretion disorder (2015-11-10),
3. 8507545 - Cytotoxic T cell activator comprising EP4 agonist (2013-08-13),
4. 8207223 - Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient (2012-06-26),
5. 8088802 - N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation (2012-01-03),
6. 7858610 - [object Object] (2010-12-28),
7. 7629369 - N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation (2009-12-08),
8. 7608637 - Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient (2009-10-27),
9. 7335776 - Remedies for depression containing EP1 antagonist as the active ingredient (2008-02-26),
10. 7256211 - 8-azaprostaglandin derivatives and medical use thereof (2007-08-14),
11. 7235667 - N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation (2007-06-26),
12. 7217701 - Intracellular calcium concentration increase inhibitors (2007-05-15),
13. 7196198 - Benzoic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient (2007-03-27),
14. 6710205 - Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient (2004-03-23),
15. 6288119 - 11,15-O-dialkylprostaglandin E derivatives, process for producing the same, and drugs containing the same as the active ingredient (2001-09-11),

Title: Takayuki Maruyama: Innovator in Cardiovascular Treatments

Introduction

Takayuki Maruyama is an accomplished inventor based in Mishima-gun, Japan, with an impressive portfolio of 20 patents. His work primarily focuses on advancing treatments for cardiovascular diseases, showing a strong commitment to improving patient care and quality of life.

Latest Patents

Among his notable recent patents, Maruyama developed an advanced heart failure treatment material that serves as a myocardial/cardiovascular regeneration device. This innovative device is designed to self-assemble, making it commercially viable without the need for cell-culturing, thus offering a cell-free solution to treat intractable cardiovascular diseases. The device aims to address urgent issues in advanced heart failure by enhancing therapeutic effects that can save lives and improve the patient's quality of life (QOL). Additionally, he has contributed to the field with a therapeutic agent for urinary excretion disorder, specifically disclosing an EP1 antagonist, represented by a unique chemical formula.

Career Highlights

Takayuki Maruyama has worked with leading pharmaceutical companies, including Ono Pharmaceutical Co., Ltd. and Ono Pharmaceuticals Co., Ltd. His contributions in these roles have positioned him as a key player in the development of innovative treatments in the healthcare sector.

Collaborations

Throughout his career, Maruyama has collaborated with talented professionals, including Kaoru Kobayashi and Yuuki Nagao. These partnerships have further enriched his research and development efforts, leading to groundbreaking advancements in cardiovascular treatment options.

Conclusion

In summary, Takayuki Maruyama stands out as a visionary inventor dedicated to tackling critical challenges in cardiovascular health. His innovative patents and collaborative spirit reflect a deep commitment to advancing medical science for the benefit of patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…